SWOT Analysis for Orchid Pharma Ltd. - Opportunity

Add SWOT widget to your site/app

Consistent Highest Return Stocks over Five Years - Nifty500

Annual Profit Growth higher than Sector Profit Growth

PEG lower than Industry PEG

Effectively using its capital to generate profit - RoCE improving in last 2 years

Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Companies with Low Debt

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

Top Gainers

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Lowest Momentum Scores (Technical Scores)

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Declining profits every quarter for the past 3 quarters

Declining Revenue every quarter for the past 2 quarters

Declining Net Cash Flow : Companies not able to generate net cash

Fall in Quarterly Revenue and Net Profit (YoY)

Near 52 Week Low

Weak Momentum: Price below Short, Medium and Long Term Averages

Degrowth in Revenue, Profits and Operating Profit Margin in recent results (QoQ)

Increasing Trend in Non-Core Income

RSI indicating price weakness

Highest fall from 52 Week High

Near 52 Week Low

Stocks Underperforming their Industry Price Change in the Quarter

FII / FPI or Institutions increasing their shareholding

MFs increased their shareholding last quarter

Mutual Funds Increased Shareholding over the Past Two Months

Red Flags: Firms linked to ongoing regulatory investigations/legal cases

US FDA Warning Letter

High Piotroski Score - Companies with strong financials

Rising Delivery Percentage Compared to Prev Day

Decline in Net Profit with falling Profit Margin (QoQ)